Flaura2 Phase III Clinical Study Shows Overall Survival Benefit Trend Consistent with Global Data in Chinese Population Treated with Tagrisso and Chemotherapy for EGFR Mutant Advanced Non-Small Cell Lung Cancer September 19, 2026
The analysis of overall survival in the Chinese subgroup of FLAURA2 showed that the benefit-risk profile of the combination regimen...